...
首页> 外文期刊>International journal of endocrinology >Elevated Serum IL-17 Expression at Cessation Associated with Graves’ Disease Relapse
【24h】

Elevated Serum IL-17 Expression at Cessation Associated with Graves’ Disease Relapse

机译:Graves病复发与停止时血清IL-17表达升高

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background. Antithyroid drug (ATD) treatment occupies the cornerstone therapeutic modality of Graves’ disease (GD) with a high relapse rate after discontinuation. This study aimed to assess potential risk factors for GD relapse especially serum interleukin-17 (IL-17) expression. Methods. Consecutive newly diagnosed GD patients who were scheduled to undergo ATD therapy from May 2011 to May 2014 were prospectively enrolled. Risk factors for GD relapse were analyzed by univariate and multivariate Cox proportional hazard analyses. The association between serum IL-17 expression at cessation and GD relapse was analyzed with relapse-free survival (RFS) by the Kaplan–Meier survival analysis and log-rank test. Results. Of the 117 patients, 72 (61.5%) maintained a remission for 12 months after ATD withdrawal and 45 (38.5%) demonstrated GD relapse. The final multivariate Cox analysis indicated elevated IL-17 expression at cessation to be an independent risk factor for GD relapse within 12 months after ATD withdrawal (HR 3.04, 95% CI 1.14–7.67, ). Patients with higher expressions of IL-17 (≥median value) at cessation demonstrated a significantly higher RFS than those with lower levels by the Kaplan–Meier analysis and log-rank test (). Conclusions. This present study indicated elevated serum IL-17 expression at cessation to be a predictor for GD relapse within 12 months.
机译:背景。抗甲状腺药物(ATD)占据了格雷夫斯病(GD)的基石治疗方式,停药后复发率很高。这项研究旨在评估GD复发的潜在危险因素,尤其是血清白介素17(IL-17)的表达。方法。前瞻性纳入计划于2011年5月至2014年5月连续接受新诊断的GD患者。 GD复发的危险因素通过单因素和多因素Cox比例风险分析进行了分析。通过Kaplan-Meier生存分析和log-rank检验,采用无复发生存(RFS)分析了停止时血清IL-17表达与GD复发之间的关系。结果。在117例患者中,有72例(61.5%)在ATD撤药后维持缓解12个月,而45例(38.5%)表现为GD复发。最终的多变量Cox分析表明,停药后12个月内IL-17表达升高是GD复发的独立危险因素(HR 3.04,95%CI 1.14-7.67,)。通过Kaplan–Meier分析和对数秩检验,在停止时IL-17表达较高(≥中值)的患者的RFS明显高于水平较低的患者。结论。本研究表明,停止时血清IL-17表达升高可预测12个月内GD复发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号